Daewon Pharmaceutical Co., Ltd. (KRX:003220)
12,990
+40 (0.31%)
Last updated: Sep 8, 2025, 10:23 AM KST
Daewon Pharmaceutical Revenue
Daewon Pharmaceutical had revenue of 143.86B KRW in the quarter ending June 30, 2025, with 4.27% growth. This brings the company's revenue in the last twelve months to 603.74B, up 6.68% year-over-year. In the year 2024, Daewon Pharmaceutical had annual revenue of 598.16B with 13.51% growth.
Revenue (ttm)
603.74B
Revenue Growth
+6.68%
P/S Ratio
0.46
Revenue / Employee
470.57M
Employees
1,283
Market Cap
279.49B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 598.16B | 71.21B | 13.51% |
Dec 31, 2023 | 526.95B | 48.07B | 10.04% |
Dec 31, 2022 | 478.88B | 124.71B | 35.21% |
Dec 31, 2021 | 354.18B | 45.68B | 14.81% |
Dec 31, 2020 | 308.50B | -9.33B | -2.93% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |